Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
29 avr. 2019 08h05 HE
|
Catalyst Biosciences, Inc.
A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting...
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
03 avr. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will...
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
02 avr. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa...
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
01 avr. 2019 12h45 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor...
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
07 mars 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding Completed a full immunogenicity analysis for DalcA, plan to...
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
06 mars 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
08 févr. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Results from the study demonstrate that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding Enrollment in the Phase 2 portion of the...
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
06 févr. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector Data presented at the 12th Annual...
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
05 févr. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
31 janv. 2019 08h30 HE
|
Catalyst Biosciences, Inc.
Oral and poster presentations on updated interim data from the Phase 2/3 trial of MarzAA for the treatment of hemophilia A or B with inhibitors Poster presentation on preclinical data of CB 2679d-GT,...